Article
Protocol for Non-viral HDR-based CRISPR/Cas9 platform for small custom editing in primary T cells
2026-02-01
Abstract excerpt
<h4>Summary</h4> CRISPR/Cas9 enables precision gene editing via HDR for mutation correction and disease modelling. This protocol describes an 8-day non-viral HDR workflow for editing primary patient and healthy donor T cells, including reagent design, editing, on-target detection, and flow cytometry. The protocol was developed under research-grade conditions but supports scaling up and the transition to preclinic...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 762db10f-8230-52bf-ac7a-2578d7eba071
- DOI
- 10.64898/2026.02.01.703084
